SAGE-547 for Severe Postpartum Depression
About this title
Read the official source — NCT02285504This study evaluated the safety and effectiveness of SAGE-547 for people with depression.
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of SAGE-547 for people with depression.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 45 years. Other eligibility criteria applied.
- Listed locations
- Chapel HillSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 4
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 45 Years
- Official registry ID
- NCT02285504
- Official title
Show the full official title
An Open-Label Proof-of-Concept Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-547 Injection in the Treatment of Adult Female Patients With Severe Postpartum Depression
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Chapel Hill
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of SAGE-547 for people with depression.
Who is behind this study?
The study sponsor is Supernus Pharmaceuticals, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including SAGE-547.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 45 years. Other eligibility criteria applied.
